QC
VIR icon

Quadrature Capital’s Vir Biotechnology VIR Stock Holding History

Quadrature Capital’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$313K Sell
30,696
-44,962
-59% -$428K ﹤0.01% 1186
2026
Q1 		$678K Buy
75,658
+25,858
+52% +$206K 0.01% 690
2025
Q4 		$300K Buy
+49,800
New +$297K ﹤0.01% 848

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Quadrature Capital's VIR Position: Q2 2026 in Review

Quadrature Capital reduced its Vir Biotechnology (VIR) stake by 59% in Q2 2026, selling an estimated $428K and leaving 30,696 shares worth $313K. The position accounts for ﹤0.01% of the portfolio, ranked #1186.

Quadrature Capital first reported a position in VIR in Q4 2025 and has held it in 3 quarters since. The position peaked at $678K in Q1 2026. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Quadrature Capital held 30,696 shares of Vir Biotechnology worth $313K as of Q2 2026.
  • Quadrature Capital sold 44,962 Vir Biotechnology shares in Q2 2026, an estimated $428K.
  • Vir Biotechnology made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1186 holding.
  • Quadrature Capital first reported a position in Vir Biotechnology in Q4 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Vir Biotechnology position peaked at $678K in Q1 2026.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.